Molecular Partners

Riding our bikes to work helps us get into high gear at the office! Over the past two months, we’ve enjoyed taking part in the #BikeToWork challenge, the largest bike and health promotion campaign in Switzerland. Thank you to all who participated, who together biked an impressive 8803 km!

Last month at #SNMMI we debuted our first #RadioDARPin therapeutic (RDT) candidate, MP0712, in co-development with Orano Med. 212Pb-labeled MP0712 is designed to precisely target DLL3-expressing tumor cells and is being developed for small cell lung cancer patients. Learn more about “Our DARPin Approach to Radiopharmaceuticals” in this blog by Daniel Steiner, SVP Research & Technology.

This week Molecular Partners is at the Gordon Research Conferences Radionuclide Theranostics for the Management of Cancer to share insights about our #RadioDARPin Therapy (RDT) platform and our first RDT candidate, MP0712, targeting DLL3 in small cell lung cancer a 212Pb-labeled and DLL3-targeting RDT for small cell lung cancer patients in co-development with Orano Med.    Join Michael Stumpp, EVP Projects, for his talk on July 10th at 9:00 AM ET and Alessandra Villa, Director Lead Generation, for her poster on July 11th at 4:00 PM ET to learn about our progress.   View the full conference agenda here: https://bit.ly/3zaIPpB

Wishing our U.S.-based teammates, friends and families a very happy Independence Day!

#ICYMI Molecular Partners had a busy month attending #ASCO, #BIO2024, #SNMMI and #EHA2024! Catch up on updates across our pipeline by checking out our recent presentations #RadioDARPin #SwitchDARPin: https://bit.ly/4arzTcC 

Cancer immunotherapy, or immuno-oncology, is a form of cancer treatment that uses the power of the body’s own immune system to prevent, control and eliminate cancer. Molecular Partners is proud to be part of the R&D community that makes #CancerImmunotherapyMonth possible. Our MP0317 and MP0533 programs, as well as our #SwitchDARPin platform, maximize the versatility of #DARPins to create novel therapeutics for #cancer patients worldwide. Learn more: https://bit.ly/3xjSQ3u

Happy #PrideMonth from Molecular Partners! We are committed to fostering a safe and inclusive culture where everyone can come to work as their true self. #Pride2024

Today, our EVP Projects Michael Stumpp will be participating in a virtual fireside chat at the Cowen Inc. 2nd Annual Radiopharmaceutical Innovation Summit and will share progress on our recently debuted #RadioDARPin therapy (RDT) candidate MP0712, including positive preclinical data that show strong support for MP0712’s clinical development in small-cell lung cancer.    MP0712 is in co-development with Orano Med.    Tune in to the webcast at 10:40 AM ET: https://bit.ly/45mz97J   #radiopharmaceuticals 

Today, we are excited to present pre-clinical data on MP0621, our first program of our Switch-DARPin platform, at #EHA2024. MP0621, a cKIT x CD16a x CD47 #SwitchDARPin, is designed as a next-gen conditioning regimen for hematopoietic stem cell transplantation (#HSCT) in acute myeloid leukemia (#AML) and beyond. We will present targeted depletion of cKit+ cells in the bone marrow while preventing elimination of circulating immune cells and demonstrating added benefit of conditional CD47 blockade.   Learn more about this program from Senior Director Immuno-Oncology Alexander Link and SVP Research & Early Development Anne Goubier at our poster tonight at 6 PM CET.   Full announcement here: bit.ly/3x8rv4e

Today at #SNMMI, Senior Director Radiotherapeutics Christian Lizak, PhD will present promising preclinical data, demonstrating positive biodistribution, antitumor efficacy and tolerability by MP0712, our first development program of our RDT franchise and Lead-212 #RadioDARPin therapeutic (RDT) targeting DLL3, which we co-develop with Orano Med in small cell lung cancer. See the full update here: https://bit.ly/3RrqYRF